Nick Challoner appointed CEO of Ingenza to drive further growth
July 4, 2025Business Services, Manufacturing and Production CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president
Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
July 3, 2025Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …
Carthera receives EMA endorsement for orphan medical device status of SonoCloud
July 2, 2025Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging
French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …
SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant
July 1, 2025Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine
SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
July 1, 2025Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
June 30, 2025Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
June 30, 2025Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
Defining neighbourhood working: big picture or local lens?
June 27, 2025Business Services Gateway to Local Adoption, NHS England, neighbourhood working
In the first of the Gateway to Local Adoption series, Visions4Health caught up with Dr Nick Merrifield to discuss his views on …
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
June 27, 2025Research and Development Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …
STENTiT treats first patient with regenerative stent for limb preservation
June 27, 2025Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold
STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …
Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation
June 27, 2025Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications
Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases
June 27, 2025Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners
Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
Unlocking the gateway to ‘precision’ UK market access
June 27, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health
As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …
PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards
June 26, 2025Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health
PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses
June 26, 2025Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation
Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
